Thyroid dysfunction in chronic myeloid leukemia patients on nilotinib

Abstract

BACKGROUND: The use of tyrosine kinase inhibitors has dramatically improved the prognosis ofchronic myeloid leukemia (CML). Nilotinib has been reported to be associated with hypothyroidismand hyperthyroidism.OBJECTIVES: The current study aims to evaluate the prevalence of thyroid dysfunction in a sampleof Iraqi patients with CML (chronic phase) treated with nilotinib and its possible association with gradeof other hematological parameters.PATIENTS AND METHODS: Thirty‑one patients with CML and the same number of healthy controlswere enrolled in this cross‑sectional study. All the patients were on nilotinib hydrochloride for at least6 months.RESULTS: Approximately 10% of the patients were having hypothyroidism and 3% were hyperthyroidwhile the rest (87%) were normal regarding thyroid function. There was a significant differencebetween the study and control group in thyroid stimulating hormone levels (P < 0.05) with the levelbeing higher in the study group.CONCLUSION: Thyroid dysfunction, particularly hypothyroidism is a clinically important